Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMP: Infliximab Dose Increase vs. Adding Immunosuppressant in IBD
NCT03370601Terminated
- Sponsor
- CHU de Lille
- Start
- Jan 2017
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC) (2 arms), sponsored by CHU de Lille. Primary endpoint: Number of patients in Clinical remission at 52 weeks. Started Jan 2017; status: terminated.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03370601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370601.